OrthoSensor Launches Landmark Medical Education Event on Soft Tissue Balancing Techniques in Conjunction with the 2014 CCJR Spring Meeting Las Vegas event will include bioskills training, podium presentations and VERASENSE demonstrations
DANIA BEACH, Fla., May 15, 2014 /PRNewswire/ -- OrthoSensor Inc., the leader in Intelligent Orthopaedics, today announced the launch of a new surgical training event focused on soft tissue balancing during total knee replacement in conjunction with the Fifteenth Annual Current Concepts in Joint Replacement (CCJR) Spring 2014 meeting to take place May 18 – 21, 2014 in Las Vegas, Nevada.
OrthoSensor will kick off activities at CCJR on Sunday, May 18, 2014 with its new surgical training event, Mastering Soft Tissue Balancing Techniques (MSTB) in Total Knee Arthroplasty (TKA) at the Oquendo Center. The course will be chaired by Dr. Leo A. Whiteside and Dr. Martin W. Roche and will include a mix of didactic and hands-on learning. The course features a world class faculty including, Dr. Thomas M. Coon, Dr. Jeffrey H. DeClaire, Dr. Kenneth A. Gustke, Dr. Matthew C. Morrey and Dr. Robert J. Tait. More than 30 surgeons from seven countries will participate. The OrthoSensor MSTB Course will be held at the Oquendo Center just prior to the 2014 CCJR Spring Meeting at the Aria Resort & Casino at CityCenter.
During the OrthoSensor MSTB program, participants will have the opportunity to learn the principles of balance and soft tissue management in TKA as well as how to best utilize OrthoSensor's VERASENSE Knee System surgical sensors to optimize surgical technique and outcomes. The VERASENSE Knee System combines a single-use intelligent tibial insert trial with an intuitive user interface to enable evidenced-based surgical decisions regarding component position and soft-tissue releases to achieve balance and stability through a full range of motion. Participants will also take part in hands-on bioskills training covering soft tissue releases for varus and valgus deformities as well as other indications and clinical scenarios in TKA.
"Soft tissue balance impacts many of the postoperative criteria for a successful knee replacement," said Thomas M. Coon, M.D., of the Coon Joint Replacement Institute in St. Helena, California. "The VERASENSE Knee system is the first technology to deliver quantitative data on how well the knee is balanced, and we're finding that patients whose knees have been quantifiably balanced with VERASENSE demonstrate better function, higher activity levels, decreased pain and overall increased patient satisfaction."
One-year clinical results from an ongoing multicenter evaluation have shown that patients whose knees were quantifiably balanced using VERASENSE are statistically more likely to achieve reduced pain, improved function, and greater activity levels. These VERASENSE-balanced patients also showed greater improvements in patient satisfaction, with 97% saying they were satisfied to very satisfied compared to 82% of patients with unbalanced knees, one year after surgery.
Additional OrthoSensor Events During CCJR
- OrthoSensor will exhibit its VERASENSE technology during the CCJR meeting at the OrthoSensor booth and those of its major implant partners.
- Kenneth A. Gustke, M.D. of the Florida Orthopaedic Institute will give a podium presentation during CCJR on clinical experience and outcomes with the VERASENSE Knee System. The presentation, titled "Smart Trials Assist Placement, Alignment & Balance: The Trinity of TKA", will take place on Monday, May 19 at 5:36 p.m. as the lead-off talk in the Tips, Techniques and Technologies in Knee Arthroplasty session led by Dr. Jay R. Lieberman.
Jay Pierce, President and Chief Executive Officer of OrthoSensor, said, "We recently launched our third generation of VERASENSE sensors and software, and are extremely excited about the usability and reliability improvements we've achieved. We're also looking forward to demonstrating VERASENSE on the Stryker Triathlon, Biomet Vanguard, Zimmer NexGen and Smith & Nephew Journey II implant systems during CCJR Spring 2014. We believe that the enhancements we've made will further enable our technology to support evidence-based decisions regarding soft-tissue releases to achieve balance and stability through a full range of motion. Our goal is to continue to partner with the leading orthopaedic device companies and healthcare providers to leverage our unique technologies to continue to enable evidence-based decisions across the spectrum of orthopaedic care."
OrthoSensor, Inc. develops and commercializes intelligent orthopaedic devices and data services that provide quantitative feedback to surgeons and hospitals. The company's intelligent orthopaedic devices utilize advanced proprietary sensor and communications technologies coupled with the company's innovative software products to enable evidence-based orthopaedic surgery and a vision of improving patient outcomes and reducing the cost of treating musculoskeletal disease.
OrthoSensor and VERASENSE are trademarks of OrthoSensor, Inc.
FOR MORE INFORMATION:
SOURCE OrthoSensor, Inc.